Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 35

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 35
---
 subsidiaries.

(3) Functional and Presentation Currency

The consolidated financial statements are presented in Japanese Yen ("JPY"), which is the functional currency of the Company. All financial information presented in JPY has been rounded to the nearest million JPY, except when otherwise indicated. In tables with rounded figures, sums may not add up due to rounding.

2. Material Accounting Policies

During the year ended March 31, 2025, the material accounting standards applied in Takeda’s consolidated financial statements were consistent with those applied in the prior year's consolidated financial statements.

(Operating Segment Information)

Takeda comprises a single operating segment and is engaged in the research, development, manufacturing, marketing and out-licensing of pharmaceutical products. This is consistent with how the financial information is viewed in allocating resources, measuring performance, and forecasting future periods by the CEO who is Takeda’s Chief Operating Decision Maker.

<div align='center'>28</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

(Earnings Per Share)

The basis for calculating basic and diluted earnings per share (attributable to owners of the Company) is as follows:

|                                                                                                        |     | For the year ended March 31, |      2024 |     |     |      2025 |
|:-------------------------------------------------------------------------------------------------------|:----|:-----------------------------|----------:|:----|:----|----------:|
| Net profit for the year attributable to owners of the Company:                                         |     |                              |           |     |     |           |
| Net profit for the year attributable to owners of the Company JPY (millions)                           |     |                              |   144,067 |     |     |   107,928 |
| Net profit used for calculation of earnings per share JPY (millions)                                   |     |                              |   144,067 |     |     |   107,928 |
| Weighted-average number of ordinary shares outstanding during the year (thousands of shares) [basic]   |     |                              | 1,564,450 |     |     | 1,578,873 |
| Dilutive effect (thousands of shares)                                                                  |     |                              |    15,893 |     |     |    26,450 |
| Weighted-average number of ordinary shares outstanding during the year (thousands of shares